San Francisco - Aug 06, 2025 - Mission Bio, a South San Francisco-based leader in single-cell multi-omics, announced, the successful completion of an equity financing round led by Ally Bridge Group, with participation from existing investors including Novo Holdings, Mayfield, Cota Capital, and Agilent Technologies. The undisclosed funding amount will accelerate innovations in the Tapestri Platform, the industry’s only single-cell tri-omics solution, which now integrates targeted gene expression with genotype and protein analysis. This investment will drive clinical adoption, expand commercial partnerships, and enhance the platform’s applications in cancer research, pharmaceutical development, and cell and gene therapies, targeting the $20 billion next-generation sequencing (NGS) and flow cytometry market.
The equity financing round, led by Ally Bridge Group—a global life sciences investor with a portfolio including ProfoundBio and Pulmonx—builds on Mission Bio’s $70 million Series C in 2020, bringing total funding to over $212 million. The funds will support:
- Platform Innovation: Developing new tri-omics assays for solid tumors and advanced therapies.
- Commercial Partnerships: Expanding collaborations with biopharma and diagnostic firms like BioLegend and Integrated DNA Technologies.
- Clinical Adoption: Scaling use in clinical trials and translational research for personalized treatment strategies.
- Team Growth: Strengthening R&D and commercial teams to meet global demand.
| Funding Round | Amount | Year | Lead Investors | Supporting Investors |
|---|---|---|---|---|
| Series A | $10M | 2017 | Mayfield Fund | Not disclosed |
| Series B | $30M | 2018 | Agilent Technologies | Not disclosed |
| Series C | $70M | 2020 | Novo Growth | Soleus Capital, Mayfield, Cota, Agilent |
| Series Unknown | Undisclosed | 2025 | Ally Bridge Group | Novo Holdings, Mayfield, Cota, Agilent, others |
| Total Raised | $212M+ | – | – | – |
Charlie Silver, CEO and co-founder, stated, “This funding accelerates our mission to eliminate cancer by providing researchers and clinicians with unprecedented insights into disease at the single-cell level.”
Mission Bio’s Technology
The Tapestri Platform is the only single-cell tri-omics solution, simultaneously analyzing single nucleotide variants (SNVs), copy number variants (CNVs), protein expression, and targeted gene expression from the same cell. This enables researchers to identify rare cell populations, track minimal residual disease (MRD), and understand therapy resistance with unprecedented precision. Key features include:
- Tri-Omics Capability: Integrates DNA, protein, and gene expression analysis for comprehensive biomarker discovery.
- High-Throughput Processing: Analyzes up to 10,000 cells, integrating with existing NGS workflows.
- Visualization Tools: Tapestri Pipeline and Insights software provide UMAP, violin, and fish plots for actionable insights.
- Customizable Panels: Offers pre-designed panels for AML, multiple myeloma, and genome editing, with custom assay options.
Adopted by NCI cancer centers like MD Anderson and Memorial Sloan Kettering, Tapestri has powered studies sequencing over 1 million cells, including a landmark AML atlas. The June 2025 addition of targeted gene expression enhances its utility in derisking cancer drug development.
Leadership and Expertise
Spun out of UCSF in 2011, Mission Bio is led by CEO Brian Kim (appointed 2024) and CTO Nigel Beard. The team’s expertise in microfluidics, genomics, and bioinformatics drives Tapestri’s innovation. Strategic hires, like Chief Commercial Officer Roman Haehn in 2025, support market expansion. The board includes Robert Ghenchev of Novo Holdings, reflecting strong investor confidence.
Industry Impact and Challenges
The $20 billion NGS and flow cytometry market is driven by demand for precision medicine, with single-cell analysis projected to grow significantly by 2030. Tapestri addresses critical needs in oncology and cell therapies, where failed clinical trials cost $50 billion annually. A May 2025 Nature publication validated Tapestri’s role in tracking precancerous clones, enhancing its clinical relevance.
Challenges include high costs (up to $40,000 per study) and integration complexity. Mission Bio mitigates these through reagent rental programs, seamless NGS integration, and partnerships with BioLegend for antibody panels. Competition from 10x Genomics, Scale Bio, and Atrandi Biosciences persists, but Tapestri’s tri-omics capability and clinical focus provide a competitive edge.
Stakeholder Perspectives
Frank Yu of Ally Bridge Group said, “Mission Bio’s Tapestri Platform is unmatched in its ability to deliver single-cell insights, transforming how we understand and treat cancer.” Stephen Chung, MD, from UT Southwestern, added, “The ability to connect mutations with immunophenotypes at single-cell resolution has been a game-changer for discovering disease stem cells.”
Future Outlook
Mission Bio plans to expand Tapestri’s applications in solid tumors, AML MRD, and gene-edited therapies, with new assays slated for 2026. Partnerships with Onconova Therapeutics and the University of Miami will drive translational research. The company aims to support 10,000 clinical trials by 2030, leveraging its growing presence in NCI cancer centers and biopharma.
Source : Mission Bio’s Technology
